Citations

Mayo Clinic

Showing 10 of 108599 citations.

Diplomate in Medical Laboratory Immunology Certification Examination: A New Chapter for Medical Laboratory Immunology
Khanolkar, Aaruni , Spiczka, Amy, Bonfield, Tracey L. , Alexander, Thomas S. , Schmitz, John L. , Boras, Diana , Fong, Karen, Nandiwada, Sarada L. , Miller, Gerald C., Tebo, Anne E.

ImmunoHorizons | August 28, 2023 | Volume: 7 | Issue: 8 | Pages: 600-610

10.4049/immunohorizons.2300030 | PMID 37639224 Get It

Abstract It is indeed a privilege to be an immunologist in what is arguably the golden age of immunology. From astounding advances in fundamental knowledge to groundbreaking immunotherapeutic offerings, immunology has carved out an enviable niche for itself in basic science and clinical medicine. The need and the vital importance of appropriate education, training, and certification in clinical immunology was recognized by the World Health Organization as far back as 1972. In the United States, Ph.D. scientists with board certification in medical laboratory immunology have served as directors of high-complexity Clinical Laboratory Improvement Amendments– and College of American Pathologists–certified clinical immunology laboratories since 1977. From 1977 to 2017, board certification for medical laboratory immunology was administered by the American Society for Microbiology through the American Board of Medical Laboratory Immunology examination. The American Board of Medical Laboratory Immunology examination was phased out in 2017, and in the fall of 2019, the American Society for Clinical Pathology (ASCP) Board of Certification (BOC) examination committee took on the responsibility of developing a new doctoral-level certification examination for medical laboratory immunology. This transition to the ASCP BOC represents a well-deserved and much-needed recognition of the rapid advances in and the highly specialized nature of medical laboratory immunology and its ever-increasing relevance to patient care. This new ASCP BOC certification is called the Diplomate in Medical Laboratory Immunology, and, as of April 1, 2023, it is now available to potential examinees. In this report, we describe the examination, eligibility routes, and potential career pathways for successful diplomates.
The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions
Camilleri, Michael

Neurogastroenterology & Motility | August 28, 2023 | Volume: 36 | Issue: 2 | Pages: No page available

10.1111/nmo.14660 | PMID 37638839 Get It

AbstractPurposeThe objectives of this review are to summarize the role of gastric motor functions in the development of satiation (defined broadly as postprandial fullness) and satiety (reduced appetite or postponing desire to eat after a meal) and their impact on weight change. The specific topics are the methods of measurement of gastric emptying and accommodation and their impact on food intake, satiation, and satiety. A second focus contrasts bariatric surgery to endoscopic gastroplasty that alter gastric emptying and incretin responses in markedly divergent manners.BackgroundThe hormone, GLP‐1, retards gastric emptying and increases gastric accommodation through vagally‐mediated effects. Indeed, these effects provide the basis for the association of altered gastric emptying in the appetite and weight loss responses to pharmacological interventions particularly by those acting on receptors of incretin agonists such as liraglutide and the dual agonists, tirzepatide and cotadutide, all of which retard gastric emptying. In fact, retardation of gastric emptying and gastrointestinal adverse effects have been shown to contribute in part to the weight loss in response to this class of pharmacological agents.SummaryThe motor functions of the stomach are relevant to postprandial fullness and to interventions aimed at weight loss in people with obesity.
How Molecular Discoveries Have Changed Liver Tumor Pathology: A Brief Review
Taheri, Negar , Graham, Rondell P.

Archives of Pathology & Laboratory Medicine | August 28, 2023 | Volume: 148 | Issue: 5 | Pages: e96-e102

10.5858/arpa.2023-0099-ra | PMID 37639429 Get It

Context Recent molecular discoveries have led to improved understanding of tumor biology and the development of new diagnostic assays. Objective To review primarily 3 examples of liver tumors and to briefly illustrate how recent molecular discoveries have altered clinical liver pathology practice. Data Sources First, we will discuss fibrolamellar carcinoma, which will be the main focus of discussion, as an example for new diagnostic tests that have been developed as a result of molecular discoveries. Additional information on the role of molecular diagnostics in hepatocellular adenoma and hepatocellular carcinoma will be provided. Second, we will use the example of epithelioid hemangioendothelioma as an example of how new diagnostic tools, based on molecular discoveries, may support improved prognostication. Finally, we will use the example of intrahepatic cholangiocarcinoma as an example of a liver tumor where new molecular discoveries have identified tractable therapeutic targets and led to new effective therapies. This portion of the manuscript will also include a description of the anatomic and molecular differences between intrahepatic, hilar, and extrahepatic cholangiocarcinoma. Conclusions Fueled by molecular discoveries, new and better diagnostic tests and therapeutic targets have improved clinical care in patients affected by liver tumors.
Volumetric T 2 ‐weighted spin echo imaging with improved SNR using localized
Kim, Dahan , Wang, Dinghui , Chao, Tzu Cheng , Pipe, James G. , Campeau, Norbert, Pipe, James G , Campeau, Norbert G.

Magnetic Resonance in Medicine | August 28, 2023 | Volume: 90 | Issue: 6 | Pages: 2261-2274

10.1002/mrm.29788 | PMID 37639386 Get It

Abstract Purpose To demonstrate T 2 ‐weighted (single‐echo) spin‐echo (SE) imaging with near‐optimal acquisition efficiency by applying SNR‐efficient RF slice encoding and spiral readout. Methods A quadratic‐phase (frequency swept) excitation RF pulse replaced the conventional excitation in T 2 ‐weighted SE sequence to excite a thick slab that is internally spatially encoded by a variable phase along the slice direction. Highly overlapping slabs centered at every desired slice location were acquired in multiple passes, such that the entire imaging volume was excited by contiguous slabs in any given pass. Following 90° excitation, each slab was refocused with a conventional 180° RF to produce a SE signal, followed by a spiral in‐out readout. A noise‐insensitive reconstruction removed the quadratic phase in the spatial frequency domain, yielding desired slice resolution and improved SNR. Results Increasing the RF frequency sweep (hence, excitation width) allowed more frequent encoding of each slice over the multiple passes, improving final image SNR, until crosstalk ensued at excessive slab widths compared to their center‐to‐center spacing. With an optimized slab width, the proposed technique used all passes to acquire every prescribed slice, with substantially improved SNR over conventional SE or 2D‐turbo‐spin‐echo (TSE) scans. Quantitative SNR measurements indicated similar SNR as 3D‐TSE, but radiologist scoring favored 3D‐TSE, mainly because of spiral‐related artifacts and possibly because of regularized reconstructions in 3D‐TSE. Conclusion Using SNR‐efficient slice excitation scheme and spiral readout helped eliminate SNR and temporal inefficiencies in conventional T 2 ‐weighted imaging, yielding SNR independent of TR or number of passes.
Steerable Ureteroscopic Renal Evacuation (SURE) for Large Renal Stones: A Multi-Institutional Center Study
Stern, Karen , Borgert, Benjamin, Wolf, J. Stuart, Stern, Karen L

Journal of Endourology | August 28, 2023 | Volume: 37 | Issue: 11 | Pages: 1179-1183

10.1089/end.2023.0424 | PMID 37639362 Get It

Background: The results of a recent pilot study suggest that steerable ureteroscopic renal evacuation (SURE) is safe and more effective in stone removal than basketing following laser lithotripsy. The objective of this retrospective study was to further assess the safety and efficacy of SURE using the CVAC ® Aspiration System (Calyxo, Inc., Pleasanton, CA) in patients with large stone burdens. Materials and Methods: Patients with a baseline stone burden of ≥10 mm who underwent SURE were identified. Subject demographics, secondary procedures, complications, and stone clearance (defined as percent baseline volume reduction) were evaluated. Subanalyses were performed to explore patients identified as high risk for percutaneous nephrolithotomy (PCNL) because (1) they were on anticoagulation or antiplatelet therapy at the time of procedure or (2) they had limited mobility due to neurologic conditions. Results: Identified patients ( N = 43) had a mean preoperative stone burden of 29 ± 12 mm and mean stone volume of 3092 ± 5002 mm 3 . Approximately one-half of patients ( n = 24, 55.8%) had CT imaging at follow-up, and of those, 8 (33.3%) had no residual stones, 22 (91.7%) had >90% stone clearance, 23 (95.8%) had >80% stone clearance, and 24 (100%) had >60% stone clearance. Stone clearance based on baseline stone burden varied between 93.8% and 98.9%. At baseline, 21 patients were anticipated to require staged ureteroscopy; however, only two of those (9.5%) needed secondary procedures. High-risk patients ( n = 22) were on anticoagulation or antiplatelet therapy ( n = 12) or had neurologic conditions ( n = 10). Stone clearance was 97% among patients in the anticoagulated cohort with postoperative CT imaging and 83% in the neurologic condition cohort. There were no device-related complications and no postoperative admissions. Conclusions: The CVAC Aspiration System is safe and effective for treating large stone burdens, including in high-risk patients, and may decrease the need for PCNL or secondary procedures. ClinicalTrials.gov Identifier: NCT04519294.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction
Desai, Milind Y. , Owens, Anjali , Wolski, Kathy , Geske, Jeffrey B. , Wang, Andrew , Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Naidu, Srihari S. , Smedira, Nicholas G. , McErlean, Ellen, Sewell, Christina , Mudarris, Lana, Gong, Zhiqun, Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Geske, Jeffrey B , Cremer, Paul C , Wang, Andrew , Saberi, Sara , Sherrid, Mark V. , Fermin, David , Schaff, Hartzell V.

JAMA Cardiology | August 28, 2023 | Volume: 8 | Issue: 10 | Pages: 968

10.1001/jamacardio.2023.3342 | PMID 37639243 Get It

Importance There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the short-term need for septal reduction therapy (SRT). Objective To examine the cumulative longer-term effect of mavacamten on the need for SRT through week 56. Design, Setting, and Participants This was a double-blind, placebo-controlled, multicenter, randomized clinical trial with placebo crossover at 16 weeks, conducted from July 2020 to November 2022. Participants were recruited from 19 US HCM centers. Included in the trial were patients with obstructive HCM (New York Heart Association class III/IV) referred for SRT. Study data were analyzed April to August 2023. Interventions Patients initially assigned to mavacamten at baseline continued the drug for 56 weeks, and patients taking placebo crossed over to mavacamten from week 16 to week 56 (40-week exposure). Dose titrations were performed using echocardiographic LVOT gradient and LV ejection fraction (LVEF) measurements. Main Outcome and Measure Proportion of patients undergoing SRT, remaining guideline eligible or unevaluable SRT status at week 56. Results Of 112 patients with highly symptomatic obstructive HCM, 108 (mean [SD] age, 60.3 [12.5] years; 54 male [50.0%]) qualified for the week 56 evaluation. At week 56, 5 of 56 patients (8.9%) in the original mavacamten group (3 underwent SRT, 1 was SRT eligible, and 1 was not SRT evaluable) and 10 of 52 patients (19.2%) in the placebo crossover group (3 underwent SRT, 4 were SRT eligible, and 3 were not SRT evaluable) met the composite end point. A total of 96 of 108 patients (89%) continued mavacamten long term. Between the mavacamten and placebo-to-mavacamten groups, respectively, after 56 weeks, there was a sustained reduction in resting (mean difference, −34.0 mm Hg; 95% CI, −43.5 to −24.5 mm Hg and −33.2 mm Hg; 95% CI, −41.9 to −24.5 mm Hg) and Valsalva (mean difference, −45.6 mm Hg; 95% CI, −56.5 to −34.6 mm Hg and −54.6 mm Hg; 95% CI, −66.0 to −43.3 mm Hg) LVOT gradients. Similarly, there was an improvement in NYHA class of 1 or higher in 51 of 55 patients (93%) in the original mavacamten group and in 37 of 51 patients (73%) in the placebo crossover group. Overall, 12 of 108 patients (11.1%; 95% CI, 5.87%-18.60%), which represents 7 of 56 patients (12.5%) in the original mavacamten group and 5 of 52 patients (9.6%) in the placebo crossover group, had an LVEF less than 50% (2 with LVEF ≤30%, one of whom died), and 9 of 12 patients (75%) continued treatment. Conclusions and Relevance Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring. Trial Registration ClinicalTrials.gov Identifier: NCT04349072
Prevalence and incidence of diastolic dysfunction in atrial fibrillation: clinical implications
Naser, Jwan A. , Scott, Christopher G. , Kennedy, Austin M , Pellikka, Patricia A. , Lin, Grace , Pislaru, Sorin V. , Borlaug, Barry A. , Scott, Christopher , Kennedy, Austin M , Pellikka, Patricia A , Sabbah, Michael S. , Borlaug, Barry A , Naser, Jwan A , Lee, Eunjung

European Heart Journal | August 28, 2023 | Volume: 44 | Issue: 48 | Pages: 5049-5060

10.1093/eurheartj/ehad592 | PMID 37639219 Get It

Abstract Background and Aims Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are intimately associated disorders; HFpEF may be overlooked in AF when symptoms are simply attributed to dysrhythmia, and incident AF may identify patients at risk for developing diastolic dysfunction (DD). This study aimed to investigate the prevalence and incidence of DD in patients with new-onset AF compared with sinus rhythm (SR). Methods Adults with new-onset AF (n = 1747) or SR (n = 29 623) and no structural heart disease were identified. Propensity score matching was performed (1:3 ratio) between AF and SR based on age, sex, body mass index, and comorbidities. Severe DD (SDD) was defined by ≥3/four abnormal parameters (medial e’, medial E/e’, tricuspid regurgitation velocity, and left atrial volume index) and ≥moderate DD (>MDD) by ≥2/4. Annualized changes in DD indices were determined. Results New-onset AF was independently associated with SDD (8% vs. 3%) and ≥MDD (25% vs. 16%); 62% of patients with AF had high-risk H2FPEF scores, and 5% had clinically recognized HFpEF. Over a median follow-up of 3.2 (interquartile range 1.6–5.8) years, DD progressed two–four-fold more rapidly in those with new-onset AF (P < .001 for all). The risk for incident DD was increased in new-onset AF [hazard ratio (95% confidence interval) 2.69 (2.19–3.32) for SDD and 1.73 (1.49–2.02) for ≥MDD]. Conclusions Patients with new-onset AF display high-risk features for HFpEF at diagnosis, emphasizing the importance of evaluating for HFpEF among symptomatic patients with AF. Patients with new-onset AF have accelerated progression in DD over time, which may identify patients with preclinical HFpEF, where preventive therapies may be tested.
Impact of concomitant gastroesophageal reflux disease symptomology on prognosis and pulmonary function of chronic hypersensitivity pneumonitis
Elkhatib, Wiaam Y., Baig, Hassan , Lee, Augustine S. , Baig, Hassan Z, Helgeson, Scott A. , Baig, Hassan Z

Lung India | August 28, 2023 | Volume: 40 | Issue: 5 | Pages: 406-411

10.4103/lungindia.lungindia_107_23 | PMID 37787352 Get It

ABSTRACT Background and Objectives: Comorbid risk factors in chronic hypersensitivity pneumonitis (CHP) are poorly characterised. Gastroesophageal reflux disease (GERD) is linked to interstitial lung diseases like idiopathic pulmonary fibrosis (IPF), but its association and treatment in CHP is less understood. This study aims to understand the role and prevalence of GERD in CHP, plus the effect of GERD treatment on lung function and mortality. Methods: A tertiary referral centre panel was retrospectively reviewed for 214 patients diagnosed with CHP based on clinical history, bronchoalveolar lavage fluid analysis, imaging and histopathology. GERD diagnostic criteria included symptomology, acid suppressive therapy use and diagnostic testing. CHP patients with GERD ( n = 89) and without GERD ( n = 125) were compared via descriptive statistical analysis. Pulmonary function, GERD diagnosis plus treatment and other comorbidities were evaluated against CHP outcomes. Results: Respective differences between diagnosis and study termination dates in the GERD population versus without GERD for functional vital capacity (FVC) were − 1 L vs − 2.5 L, diffusing capacity of the lungs for carbon monoxide (DLCO) were − 2 mL/min/mmHg versus − 1 mL/min/mmHg, per cent alive at the time of study 88% versus 81%, median date of survival 574.5 versus 850 and supplemental oxygen requirement 41% versus 37%. GERD prevalence was higher in CHP patients relative to the general population. No statistical significance was found between survival curves, oxygen requirement, smoking history, FVC, or DLCO. Conclusions: GERD could be a harmful comorbidity in CHP though may not necessarily affect survival or functional outcomes. This aligns with previous IPF studies, though remains controversial. Further research is needed regarding this association and treatment benefit.
Cerebral Microbleed Patterns and Cortical Amyloid-β: The ARIC-PET Study
Okine, Derrick , Knopman, David S. , Mosley, Thomas H. , Wong, Dean F. , Johansen, Michelle C. , Walker, Keenan A. , Jack, Clifford R. , Kantarci, Kejal , Pike, James Russell , Graff‐Radford, Jonathan , Mosley, Thomas H. , Knopman, David S. , Okine, Derrick N , Pike, James R , Gottesman, Rebecca F , Jack, Clifford R , Kantarci, Kejal , Walker, Keenan A , Johansen, Michelle C , Gottesman, Rebecca F.

Stroke | August 28, 2023 | Volume: 54 | Issue: 10 | Pages: 2613-2620

10.1161/strokeaha.123.042835 | PMID 37638398 Get It

BACKGROUND: Cerebral microbleeds (CMBs) are associated with cognitive decline, but their importance outside of cerebral amyloid angiopathy and the mechanisms of their impact on cognition are poorly understood. We evaluated the cross-sectional association between CMB patterns and cerebral Aβ (amyloid-β) deposition, by florbetapir positron emission tomography. METHODS: The longitudinal ARIC study (Atherosclerosis Risk in Communities) recruited individuals from 4 US communities from 1987 to 1989. From 2012 to 2014, the ARIC-PET (Atherosclerosis Risk in Communities - Positron Emission Tomography) ancillary recruited 322 nondemented ARIC participants who completed 3T brain magnetic resonance imaging with T2*GRE as part of ARIC visit 5 to undergo florbetapir positron emission tomography imaging. Magnetic resonance imaging images were read for CMBs and superficial siderosis; on positron emission tomography, global cortical standardized uptake value ratio >1.2 was considered a positive Aβ scan. Multivariable logistic regression models evaluated CMB characteristics in association with Aβ positivity. Effect modification by sex, race, APOE status, and cognition was evaluated. RESULTS: CMBs were present in 24% of ARIC-PET participants. No significant associations were found between CMBs and Aβ positivity, but a pattern of isolated lobar CMBs or superficial siderosis was associated with over 4-fold higher odds of elevated Aβ when compared with those with no CMBs (odds ratio, 4.72 [95% CI, 1.16–19.16]). A similar elevated risk was not observed in those with isolated subcortical or mixed subcortical and either lobar CMBs or superficial siderosis. Although no significant interactions were found, effect estimates for elevated Aβ were nonsignificantly lower ( P >0.10, odds ratio, 0.4–0.6) for a mixed CMB pattern, and odds ratios were nonsignificantly higher for lobar-only CMBs for 4 subgroups: women (versus men); Black participants (versus White participants), APOE ε4 noncarriers (versus carriers), and cognitively normal (versus mild cognitive impairment). CONCLUSIONS: In this community-based cohort of nondemented adults, lobar-only pattern of CMBs or superficial siderosis is most strongly associated with brain Aβ, with no elevated risk for a mixed CMB pattern. Further studies are needed to understand differences in CMB patterns and their meaning across subgroups.
Aerobic and Muscle-Strengthening Physical Activity, Television Viewing, and Nonalcoholic Fatty Liver Disease: The CARDIA Study
McDonough, Daniel J. , Mathew, Mahesh, Pope, Zachary , Schreiner, Pamela J. , Jacobs, David R. , VanWagner, Lisa B. , Terry, James G. , Gabriel, Kelley Pettee , Reis, Jared P. , Pereira, Mark A. , Pope, Zachary C, Terry, James G , McDonough, Daniel J , Pereira, Mark A , VanWagner, Lisa B , Jacobs, David R , Carr, J. Jeffrey

Journal of Clinical Medicine | August 28, 2023 | Volume: 12 | Issue: 17 | Pages: 5603

10.3390/jcm12175603 | PMID 37685671 Get It

Background: The prevalence of non-alcoholic fatty liver disease (NAFLD) in U.S. adults is over 30%, yet the role of lifestyle factors in the etiology of NAFLD remains understudied. We examined the associations of physical activity, by intensity and type, and television viewing with prevalent NAFLD. Methods: Cross-sectional analysis of a population-based sample of 2726 Black (49%) and White (51%) adults (Mean (SD) age, 50 (3.6) years; 57.3% female) from the CARDIA study. Exposures were aerobic activity by intensity (moderate, vigorous; hours/week); activity type (aerobic, muscle-strengthening; hours/week); and television viewing (hours/week), examined concurrently in all models and assessed by validated questionnaires. Our outcome was NAFLD (liver attenuation < 51 Hounsfield Units), measured by non-contrast computed tomography, after exclusions for other causes of liver fat. Covariates were sex, age, race, study center, education, diet quality, smoking status, alcohol consumption, and body mass index or waist circumference. Results: 648 participants had NAFLD. In the fully adjusted modified Poisson regression model, the risk ratios per interquartile range of each exposure were moderate-intensity aerobic activity, 1.10 (95% CI, 0.97–1.26); vigorous-intensity aerobic activity, 0.72 (0.63–0.82); muscle-strengthening activity, 0.89 (0.80–1.01); and television viewing, 1.20 (1.10–1.32). Relative to less active participants with higher levels of television viewing, those who participated in ≥2 h/week of both vigorous-intensity aerobic and muscle-strengthening activity and <7 h/week of television viewing had 65% lower risk of NAFLD (risk ratio = 0.35, 95% CI = 0.23–0.51). Conclusion: Adults who follow public health recommendations for vigorous-aerobic and muscle-strengthening activity, as well as minimize television viewing, are considerably less likely to have NAFLD than those who do not follow the recommendations and who have relatively high levels of television viewing.